查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2022-2028 年耐甲氧西林金黄色葡萄球菌 (MRSA) 抗生素市场
市场调查报告书
商品编码
1215733

2022-2028 年耐甲氧西林金黄色葡萄球菌 (MRSA) 抗生素市场

Methicillin-Resistant Staphylococcus Aureus (MRSA) Antibiotic Market 2022-2028
出版日期: | 出版商: Orion Market Research | 英文 | 商品交期: 2-3个工作天内

价格

全球 MRSA 抗生素市场预计在预测期内将以 5.5% 的复合年增长率显着增长，这要归功于研发活动的增加以及针对 MRSA 相关感染治疗的各种研究。 例如，2019 年 9 月，杜克大学健康中心的研究人员领导的一项研究表明，遗传易感性似乎使一个人更有可能成功抵抗抗生素耐药性葡萄球菌感染。 这一发现增加了对使某些人易患持续性耐甲氧西林金黄色葡萄球菌 (MRSA) 感染的遗传因素的重要认识，并可能导致开发更好的治疗方法。 该研究还提供了基因突变的有力证据，这些基因突变可能有助于 MRSA 感染者解决血液感染问题。 此外，厂商对达托霉素、万古霉素等先进药物的开发重点也在推动MRSA治疗市场的增长。

全球 MRSA 抗生素市场根据治疗类型、分销渠道进行细分。 根据治疗类型，市场分为万古霉素、四环素、利奈唑胺、达托霉素和脂□。 基于分销渠道，市场细分为在线医院药房和零售药房。 在上述细分市场中，四环素是另一种也影响欠市场的药物，因为它通过与细菌 30S 核醣体可逆结合来阻止细菌蛋白质合成。 四环素类抗生素对革兰氏阳性和革兰氏阴性细菌有效。

市场按地域划分如下： 北美、欧洲、亚太地区和世界其他地区。 预计亚太地区将在预测期内以最快的速度增长。 这是因为中国和印度庞大的患者群体以及印度对抗生素的无节制消费，估计将推动亚太地区 MRSA 抗生素市场的增长。

内容

第 1 章报告概述

  • 当前行业分析和增长前景
  • COVID-19 对全球 MRSA 抗生素市场的影响
  • 全球 MRSA 抗生素市场復苏情景
  • 研究方法和工具
  • 市场细分
    • 按细分
    • 按地区

第 2 章市场概述和洞察

  • 调查范围
  • 分析师见解和当前市场趋势
    • 主要发现
    • 推荐
    • 总结

第三章竞争格局

  • 默克集团。
    • 概览
    • 财务分析
    • SWOT 分析
    • 近期趋势
  • Olon 活性药物
    • 概览
    • 财务分析
    • SWOT 分析
    • 近期趋势
  • 辉瑞公司
    • 概览
    • 财务分析
    • SWOT 分析
    • 近期趋势
  • Viatris 公司
    • 概览
    • 财务分析
    • SWOT 分析
    • 近期趋势
  • 礼来公司
    • 概览
    • 财务分析
    • SWOT 分析
    • 近期趋势
  • 关键策略分析
  • COVID-19 对主要参与者的影响

第四章市场细分

  • 按治疗类型划分的 MRSA 抗生素全球市场
    • 万古霉素
    • 四环素
    • 利奈唑胺
    • 达托霉素
    • 脂□
  • MRSA 抗生素的全球市场：按分销渠道分类
    • 在线
    • 医院药房
    • 零售店

第五章区域分析

  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 意大利
    • 西班牙
    • 法国
    • 其他欧洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 其他亚太地区
  • 世界其他地方

第六章公司简介

  • Allergan Inc.
  • Baxter International Inc.
  • Cumberland Pharmaceuticals Inc.
  • Debiopharm International
  • Fresenius Kabi AG
  • Innovation Pharmaceuticals Inc.
  • Melinta therapeutics Inc.
  • Nabriva Therapeutics Plc.
  • North China Pharmaceutical Group Corp.
  • Novartis International AG
  • Paratek Pharmaceuticals Inc.
  • Sanofi-Aventis Groupe
  • Teva Pharmaceutical Industries Ltd.
  • Theravance Biopharma Inc.
  • Xellia Pharmaceuticals ApS
  • Zhejiang Hisun Pharmaceutical Co., Ltd.
  • Zhejiang Medicine Co., Ltd.
Product Code: OMR2026789

Title:Global Methicillin-Resistant Staphylococcus Aureus (MRSA) antibiotic Market Size, Share & Trends Analysis Report by Treatment Type (Vancomycin, Tetracycline, Linezolid, Daptomycin, and Lipopeptide), and by Distribution Channel (Online, Hospital Pharmacies and Retail Pharmacies) Forecast 2022-2028.

The global MRSA antibiotic market is anticipated to grow at a substantial CAGR of 5.5% during the forecast period, owing to increasing research and development activities and various studies for the treatment of infections associated with MRSA. For instance, in September 2019, a study led by Duke Health researchers showed that an inherited genetic tendency appears to increase the likelihood that a person can successfully fight off antibiotic-resistant staph infections. The finding adds important insights into the genetic factors that predispose some people to persistent methicillin-resistant Staphylococcus aureus (MRSA) infections and could lead to the development of better treatment options. The study also provides strong evidence of a genetic variant that appears to support people with MRSA to resolve their bloodstream infections. Moreover, the increasing focus of manufacturers on the development of advanced drugs such as Daptomycin, and Vancomycin, among others, are also supporting the market growth for the treatment of MRSA.

The global MRSA antibiotic market is segmented based on the treatment type, and distribution channel. Based on the treatment type, the market is segmented into vancomycin, tetracycline, linezolid, daptomycin, and lipopeptide. Based on distribution channel the market is sub segmented into online hospital pharmacies and retail pharmacies. Among the above segment, tetracyclines is another drug that also impacts the market owing it prevents bacterial protein synthesis by reversibly binding to the bacterial 30S ribosomes. They act against gram-positive and gram-negative bacteria.

Geographically market is segmented into: North America, Europe, Asia Pacific, and the Rest of the World. The Asia Pacific is set to grow at the fastest rate during the forecast period, owing to the huge patient pool in China and India and the uncontrolled consumption of antibiotics in India is estimated to fuel the growth of the MRSA antibiotic market in Asia Pacific.

The major companies serving the global MRSA antibiotic market include Merck Group., Olon Active Pharmaceutical, Pfizer Inc., Viatris Inc., Eli Lilly and Company, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in July 2021, Melinta Therapeutics announced the commercial launch of KIMYRSA, a lipoglycopeptide antibiotic that delivers a complete course of therapy for acute bacterial skin and skin structure infections. The US food and drug administration approved KIMYRSA on March 12, 2021, for the treatment of adult patients.

Research Methodology

The market study of the global MRSA antibiotic market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives as possible, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

  • Global MRSA antibiotic Market Research and Analysis by Treatment Type
  • Global MRSA antibiotic Market Research and Analysis by Distribution Channel

The Report Covers:

  • Comprehensive research methodology of the global MRSA antibiotic market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global MRSA antibiotic market.
  • Insights about market determinants that are stimulating the global MRSA antibiotic market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on The Global MRSA Antibiotic Market
  • Recovery Scenario of Global MRSA Antibiotic Market
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. BY Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Merck Group.
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Olon Active Pharmaceutical
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Pfizer Inc.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Viatris Inc.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Eli Lilly and Co.
    • 3.5.1. Overview
    • 3.5.2. Financial Analysis
    • 3.5.3. SWOT Analysis
    • 3.5.4. Recent Developments
  • 3.6. Key Strategy Analysis
  • 3.7. Impact of Covid-19 on Key Players

4. Market Segmentation

  • 4.1. Global MRSA Antibiotic Market by Treatment Type
    • 4.1.1. Vancomycin
    • 4.1.2. Tetracycline
    • 4.1.3. Linezolid
    • 4.1.4. Daptomycin
    • 4.1.5. Lipopeptide
  • 4.2. Global MRSA Antibiotic Market by Distribution Channel
    • 4.2.1. Online
    • 4.2.2. Hospital Pharmacies
    • 4.2.3. Retail Pharmacies

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Allergan Inc.
  • 6.2. Baxter International Inc.
  • 6.3. Cumberland Pharmaceuticals Inc.
  • 6.4. Debiopharm International
  • 6.5. Fresenius Kabi AG
  • 6.6. Innovation Pharmaceuticals Inc.
  • 6.7. Melinta therapeutics Inc.
  • 6.8. Nabriva Therapeutics Plc.
  • 6.9. North China Pharmaceutical Group Corp.
  • 6.10. Novartis International AG
  • 6.11. Paratek Pharmaceuticals Inc.
  • 6.12. Sanofi-Aventis Groupe
  • 6.13. Teva Pharmaceutical Industries Ltd.
  • 6.14. Theravance Biopharma Inc.
  • 6.15. Xellia Pharmaceuticals ApS
  • 6.16. Zhejiang Hisun Pharmaceutical Co., Ltd.
  • 6.17. Zhejiang Medicine Co., Ltd.

LIST OF TABLES

  • 1. GLOBAL MRSA ANTIBIOTIC MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2021-2028 ($ MILLION)
  • 2. GLOBAL VANCOMYCIN MRSA ANTIBIOTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL TETRACYCLINES MRSA ANTIBIOTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL LINEZOLID MRSA ANTIBIOTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 5. GLOBAL DAPTOMYCIN MRSA ANTIBIOTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 6. GLOBAL LIPOPEPTIDE MRSA ANTIBIOTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 7. GLOBAL MRSA ANTIBIOTIC MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
  • 8. GLOBAL MRSA ANTIBIOTIC BY ONLINE DISTRIBUTION CHANNEL MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 9. GLOBAL MRSA ANTIBIOTIC BY HOSPITAL PHARMACIES DISTRIBUTION CHANNEL MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 10. GLOBAL MRSA ANTIBIOTIC BY RETAIL PHARMACIES DISTRIBUTION CHANNEL MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 11. GLOBAL MRSA ANTIBIOTIC MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
  • 12. NORTH AMERICAN MRSA ANTIBIOTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 13. NORTH AMERICAN MRSA ANTIBIOTIC MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2021-2028 ($ MILLION)
  • 14. NORTH AMERICAN MRSA ANTIBIOTIC MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
  • 15. EUROPEAN MRSA ANTIBIOTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 16. EUROPEAN MRSA ANTIBIOTIC MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2021-2028 ($ MILLION)
  • 17. EUROPEAN MRSA ANTIBIOTIC MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
  • 18. ASIA-PACIFIC MRSA ANTIBIOTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 19. ASIA-PACIFIC MRSA ANTIBIOTIC MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2021-2028 ($ MILLION)
  • 20. ASIA-PACIFIC MRSA ANTIBIOTIC MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
  • 21. REST OF THE WORLD MRSA ANTIBIOTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 22. REST OF THE WORLD MRSA ANTIBIOTIC MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2021-2028 ($ MILLION)
  • 23. REST OF THE WORLD MRSA ANTIBIOTIC MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL MRSA ANTIBIOTIC MARKET, 2021-2028 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL MRSA ANTIBIOTIC MARKET BY SEGMENT, 2021-2028 ($ MILLION)
  • 3. RECOVERY OF GLOBAL MRSA ANTIBIOTIC MARKET, 2022-2028 (%)
  • 4. GLOBAL MRSA ANTIBIOTIC MARKET BY TREATMENT TYPE, 2021 VS 2028 (%)
  • 5. GLOBAL VANCOMYCIN MRSA ANTIBIOTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 6. GLOBAL TETRACYCLINE MRSA ANTIBIOTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 7. GLOBAL LINEZOLID MRSA ANTIBIOTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 8. GLOBAL DAPTOMYCIN MRSA ANTIBIOTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 9. GLOBAL LIPOPEPTIDE MRSA ANTIBIOTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 10. GLOBAL MRSA ANTIBIOTIC MARKET SHARE BY DISTRIBUTION CHANNEL, 2021 VS 2028 (%)
  • 11. GLOBAL MRSA ANTIBIOTIC BY ONLINE DISTRIBUTION CHANNEL MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 12. GLOBAL MRSA ANTIBIOTIC BY HOSPITAL PHARMACIES DISTRIBUTION CHANNEL MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 13. GLOBAL MRSA ANTIBIOTIC BY RETAIL PHARMACIES DISTRIBUTION CHANNEL MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 14. GLOBAL MRSA ANTIBIOTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 15. US MRSA ANTIBIOTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 16. CANADA MRSA ANTIBIOTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 17. UK MRSA ANTIBIOTICMARKET SIZE, 2021-2028 ($ MILLION)
  • 18. FRANCE MRSA ANTIBIOTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 19. GERMANY MRSA ANTIBIOTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 20. ITALY MRSA ANTIBIOTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 21. SPAIN MRSA ANTIBIOTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 22. REST OF EUROPE MRSA ANTIBIOTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 23. INDIA MRSA ANTIBIOTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 24. CHINA MRSA ANTIBIOTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 25. JAPAN MRSA ANTIBIOTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 26. SOUTH KOREA MRSA ANTIBIOTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 27. REST OF ASIA-PACIFIC MRSA ANTIBIOTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 28. REST OF THE WORLD MRSA ANTIBIOTIC MARKET SIZE, 2021-2028 ($ MILLION)